Melanoma Molecular Maps Projects



Title: Gene polymorphisms and risk of melanoma progression
Legend: Identification of markers of disease progression is a key objective in oncology for three main reasons: 1) to dissect the molecular pathways leading to disease progression and thus to develop new and more effective anticancer agents; 2) to elucidate the molecular mechanisms underlying resistance to therapeutic agents, thus favoring the development of more effective drugs and the selection of patients most likely to respond to available therapeutics; 3) to better stratify patients' risk of disease recurrence (e.g., carriers of minimal residual disease after apparently radical surgery) and thus to identify patients most likely to benefit from further treatments (e.g., post-surgical adjuvant therapy). Since they can affect all these areas of interest, single nucleotide polymorphisms (SNP) are being intensively studied in many types of tumors, including melanoma. As regards melanoma, the variety of SNP considered and the small size of the patient series so far published do not allow to draw any definitive conclusion, although available findings appear to justify further efforts in this direction. REFERENCES: 1) Gould Rothberg BE, J Natl Cancer Inst 2009, 101:452-74 2) Haass NK, Mol Diagn Ther 2009, 13:283-96 3) Gogas H, Ann Oncol 2009, 20 Suppl 6:vi8-13.
Author: Daunia Verdi, MD (updated: September 2010)

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

NCBI's Disclaimer and Copyright notice